Discounted Cash Flow (DCF) Analysis Unlevered

Kindred Biosciences, Inc. (KIN)

$9.25

+0.01 (+0.11%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 9.25 | undervalue

Operating Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 9.25
Beta 1.315
Diluted Shares Outstanding 39.29
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 8.94%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.911
Total Debt 20.44
Total Equity 363.42
Total Capital 383.86
Debt Weighting 5.32
Equity Weighting 94.68
Wacc

Build Up Free Cash

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.95-5.92-13.92-8.43-3.64-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.86
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 8.82
Equity Value -
Shares Outstanding 39.29
Equity Value Per Share -